UAM is a Spanish public university of high quality teaching and intensive research, with a firm social commitment. In the QS World University Rankings 2024, UAM is consolidated among the 200 best universities in the world, due to its high academic reputation, as well as its wide international research network. It is the fourth best university in Spain and the second in Madrid, and is among the 74 most outstanding universities in Europe. UAM campus, sustainable and easily accessible, offers a complete university experience, as they are home to all kinds of services, including libraries, museums and sports facilities, as well as cultural activities and volunteer and cooperation programs. The collaboration with the Spanish Council of Scientific Research (CSIC) in the International Excellence Campus creates a privileged environment for research and teaching, being a leader in Nanoscience, Advanced Materials and Life Sciences. In addition, UAM is part of the European Civic Alliance, one of the first pan-European campuses promoted by the European Commission. The official academic offer of the UAM includes 58 graduate degrees, 8 double degrees and 90 master’s degrees, 35 doctoral programs as well as 65 own degrees.
Centers / Institutes
Food Science Research Institute (CIAL)
C/ Nicolás Cabrera, 9 - Campus UAM Cantoblanco
28049 Madrid
Spain
The Food Science Research Institute (CIAL) , officially inaugurated on March 24, 2011, is a joint center jointly owned by the Spanish National Research Council (CSIC) and the Autonomous University of Madrid (UAM), integrated into the Campus of International Excellence (CEI) UAM+CSIC.
Between 2007 and 2014, the CIAL has defined its scope of action, configuring the governing bodies, the administrative structure and the management procedures, it has created distinctive infrastructures and facilities that strengthen the technological value and scientific excellence of the center, and it has intensified the effort to make the center visible, so that society knows and recognizes us.
The centre is structured into three research departments: Food Bioactivity and Analysis, Food Biotechnology and Microbiology, and Production and Characterisation of New Foods, which act as an organisational framework to facilitate research activities and foster scientific interaction and collaboration between the members of the institute. The centre and its researchers maintain active collaborations and exchange programmes with universities, research centres and laboratories around the world.
From the beginning, the CIAL has had the goal of becoming an international research center, leader in the field of food sciences, promoting technological development and creating wealth and well-being for society.
Specifically, the research activity carried out at the CIAL is aimed at establishing scientific evidence on the physiological effects of food and its constituents on human health and disease prevention, improving its safety and sensory properties, and identifying at the molecular level the mechanisms of biological activity of food ingredients and their metabolites in the human body, as well as their interactions with dietary components. Through new approaches and tools based on metabolomics, proteomics, genomics and microbiomics, it seeks to solve scientific challenges in the relationship between food and health, with implications for the development of nutritional interventions, which are considered the basis of the food of the future.
The ultimate goal is the application of food science in favor of health, according to the needs of the population and economic development, with the contribution of high added value products for the industry, the attraction and training of young scientists and new professionals, remaining at the service of social well-being and quality of life.
Research groups
INGREEN (Novel Food Ingredients) Group
INGREEN has over 20 years of experience in bioactive ingredients for the design of novel foods for specific health use. Research activities cover processing, chemical and biological characterization and in vitro evaluation of efficacy. Vegetal sources (plants, spices, seeds, roots or fruits), fungi and edible insects are the main raw materials investigated. Processing is largely based on the application of clean “green” technologies. In vitro bioactivity studies (antioxidant, anti-inflammatory, antitumor, antimicrobial or hypolipidemic) as well as bioaccessibility and bioavailability tests are developed, together with formulation strategies to improve efficacy (chemical/enzymatic transformation, microencapsulation techniques or delivery systems). The chemical characterization on bioactive molecules by analytical tools is also performed.
DiBaN Research Team
Diana Martín (Principal Investigator)
ORCID: 0000-0002-1082-9280
Tiziana Fornari Reali (Principal Investigator)
ORCID: 0000-0001-7371-6593
Mónica R. García-Risco
ORCID: 0000-0002-1384-6342
Luis Vázquez de Frutos
ORCID: 0000-0003-0655-4349
David Villanueva Bermejo
ORCID: 0000-0002-1762-4042
Emma Cantero Bahillo
ORCID: 0000-0002-6004-1328
Esther Rodríguez González
ORCID: 0009-0005-0857-0985
Virginia da Cunha Borges
ORCID: 0009-0003-2951-4523
Diego Martín Hernández
ORCID: 0000-0001-7058-1240
Centro de Biología Molecular Severo Ochoa (CBMSO)
Calle Nicolás Cabrera, 1
28049 Madrid
Spain
The CBM is a CSIC-UAM mixed research center that houses researchers belonging to the Higher Council for Scientific Research (CSIC) and the Autonomous University of Madrid (UAM). Founded in 1975, the CBM is one of the largest Spanish multidisciplinary research centers in biomedicine, with experience in molecular biology, biochemistry, genetics and genomics in several research areas: immunology, virology and microbiology, neuroscience and cellular and developmental biology. This extensive experience gives the center the necessary versatility to undertake new research challenges in emerging topics and unsolved biomedical problems.
More than 450 scientists and more than 90 research groups address challenges in a wide range of disciplines, and stand out for their important scientific production and technology transfer to industry and the clinic. They are supported by the most advanced technology, provided by 14 basic scientific facilities and 9 technical services with more than 65 highly experienced employees.
It is organized in four departments: Dynamics and Genome Function, Tissue and Organ Homeostasis, Interactions with the Environment, Physiologic and Pathologic Processes.
The CBM is also very committed to the modern and professional training of hundreds of researchers beginning their careers, and to the communication of research through a pioneering Communication and Dissemination Office with more than 20 years of experience.
Research groups
Functional glycogenomics
The Glycosylation is the most abundant, diverse and dynamic post-translational modification in nature, generating one of the most complex biological molecules found in nature, glycans. The group has devoted the last five years to assemble, implement and validate a novel technological platform that allows to analyze the N-glycome from biological samples just available in a few laboratories. around the world. The group has curated one of the largest collections of clinically well characterized biological samples of American trypanosomiasis biological samples (around 5000), leishmaniasis visceral and Neurocysticercosis from all stages of the diseases, before and after chemotherapy. In the last year sera from autistic, Parkinson and Alzheimer disease samples had been added. The glycomic evaluation of individuals (not populations) allows to establish associations to disease progression, therapeutic efficacy or failure and reinfections. The system has been used to analyze samples form three defined infectious disease from which we have clinically defined cohorts. From our previous studies on total sera N-glycome we have moved to study the effector profile of human Immunoglobulin G derived from its glycosylation profile. By using this novel approach, we have been allowed to identify some molecular markers for efficacy during the treatment with Benznidazole for acute Chagas disease patients, and able to discriminate the latent form active form of neurocysticercosis, previously only possible by using classical image systems like NMR or PET-TAC.
DiBaN Research Team
Pedro Bonay Miarons
ORCID: 0000-0002-4737-6318
Food Science Research Institute (CIAL)
The Food Science Research Institute (CIAL) , officially inaugurated on March 24, 2011, is a joint center jointly owned by the Spanish National Research Council (CSIC) and the Autonomous University of Madrid (UAM), integrated into the Campus of International Excellence (CEI) UAM+CSIC.
Between 2007 and 2014, the CIAL has defined its scope of action, configuring the governing bodies, the administrative structure and the management procedures, it has created distinctive infrastructures and facilities that strengthen the technological value and scientific excellence of the center, and it has intensified the effort to make the center visible, so that society knows and recognizes us.
The centre is structured into three research departments: Food Bioactivity and Analysis, Food Biotechnology and Microbiology, and Production and Characterisation of New Foods, which act as an organisational framework to facilitate research activities and foster scientific interaction and collaboration between the members of the institute. The centre and its researchers maintain active collaborations and exchange programmes with universities, research centres and laboratories around the world.
From the beginning, the CIAL has had the goal of becoming an international research center, leader in the field of food sciences, promoting technological development and creating wealth and well-being for society.
Specifically, the research activity carried out at the CIAL is aimed at establishing scientific evidence on the physiological effects of food and its constituents on human health and disease prevention, improving its safety and sensory properties, and identifying at the molecular level the mechanisms of biological activity of food ingredients and their metabolites in the human body, as well as their interactions with dietary components. Through new approaches and tools based on metabolomics, proteomics, genomics and microbiomics, it seeks to solve scientific challenges in the relationship between food and health, with implications for the development of nutritional interventions, which are considered the basis of the food of the future.
The ultimate goal is the application of food science in favor of health, according to the needs of the population and economic development, with the contribution of high added value products for the industry, the attraction and training of young scientists and new professionals, remaining at the service of social well-being and quality of life.
Research groups
INGREEN (Novel Food Ingredients) Group
INGREEN has over 20 years of experience in bioactive ingredients for the design of novel foods for specific health use. Research activities cover processing, chemical and biological characterization and in vitro evaluation of efficacy. Vegetal sources (plants, spices, seeds, roots or fruits), fungi and edible insects are the main raw materials investigated. Processing is largely based on the application of clean “green” technologies. In vitro bioactivity studies (antioxidant, anti-inflammatory, antitumor, antimicrobial or hypolipidemic) as well as bioaccessibility and bioavailability tests are developed, together with formulation strategies to improve efficacy (chemical/enzymatic transformation, microencapsulation techniques or delivery systems). The chemical characterization on bioactive molecules by analytical tools is also performed.
DiBaN Research Team
Centro de Biología Molecular Severo Ochoa (CBMSO)
The CBM is a CSIC-UAM mixed research center that houses researchers belonging to the Higher Council for Scientific Research (CSIC) and the Autonomous University of Madrid (UAM). Founded in 1975, the CBM is one of the largest Spanish multidisciplinary research centers in biomedicine, with experience in molecular biology, biochemistry, genetics and genomics in several research areas: immunology, virology and microbiology, neuroscience and cellular and developmental biology. This extensive experience gives the center the necessary versatility to undertake new research challenges in emerging topics and unsolved biomedical problems.
More than 450 scientists and more than 90 research groups address challenges in a wide range of disciplines, and stand out for their important scientific production and technology transfer to industry and the clinic. They are supported by the most advanced technology, provided by 14 basic scientific facilities and 9 technical services with more than 65 highly experienced employees.
It is organized in four departments: Dynamics and Genome Function, Tissue and Organ Homeostasis, Interactions with the Environment, Physiologic and Pathologic Processes.
The CBM is also very committed to the modern and professional training of hundreds of researchers beginning their careers, and to the communication of research through a pioneering Communication and Dissemination Office with more than 20 years of experience.
Research groups
Functional glycogenomics
The Glycosylation is the most abundant, diverse and dynamic post-translational modification in nature, generating one of the most complex biological molecules found in nature, glycans. The group has devoted the last five years to assemble, implement and validate a novel technological platform that allows to analyze the N-glycome from biological samples just available in a few laboratories. around the world. The group has curated one of the largest collections of clinically well characterized biological samples of American trypanosomiasis biological samples (around 5000), leishmaniasis visceral and Neurocysticercosis from all stages of the diseases, before and after chemotherapy. In the last year sera from autistic, Parkinson and Alzheimer disease samples had been added. The glycomic evaluation of individuals (not populations) allows to establish associations to disease progression, therapeutic efficacy or failure and reinfections. The system has been used to analyze samples form three defined infectious disease from which we have clinically defined cohorts. From our previous studies on total sera N-glycome we have moved to study the effector profile of human Immunoglobulin G derived from its glycosylation profile. By using this novel approach, we have been allowed to identify some molecular markers for efficacy during the treatment with Benznidazole for acute Chagas disease patients, and able to discriminate the latent form active form of neurocysticercosis, previously only possible by using classical image systems like NMR or PET-TAC.
DiBaN Research Team
